These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7160052)

  • 1. Effect of combination chemotherapy, duration of methotrexate administration, and patient's age on methotrexate pharmacokinetics.
    Lokiec F; Poirier O; Gisselbrecht C; Marty M; Boiron M; Najean Y
    Cancer Chemother Pharmacol; 1982; 9(3):165-8. PubMed ID: 7160052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [High-dose treatment].
    Takaku F
    Gan To Kagaku Ryoho; 1985 Apr; 12(4):830-8. PubMed ID: 3872631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia.
    Borsi JD; Moe PJ
    Cancer; 1987 Jul; 60(1):5-13. PubMed ID: 3472638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of high-dose methotrexate treatment in children.
    Bratlid D; Moe PJ
    Eur J Clin Pharmacol; 1978 Nov; 14(2):143-7. PubMed ID: 720376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of 6-hour infusion of high-dose methotrexate. Preliminary trial of monitoring high infusion doses.
    Luyckx M; Cazin JL; Brunet C; Gosselin P; Demaille MC
    Eur J Clin Pharmacol; 1985; 28(4):457-62. PubMed ID: 3839754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of prior cisplatin therapy on the pharmacokinetics of high-dose methotrexate.
    Crom WR; Pratt CB; Green AA; Champion JE; Crom DB; Stewart CF; Evans WE
    J Clin Oncol; 1984 Jun; 2(6):655-61. PubMed ID: 6539365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of 24-hour infusion of high-dose methotrexate--pharmacokinetics and toxicity.
    Goh TS; Wong KY; Lampkin B; O'Leary J; Gnarra D
    Cancer Chemother Pharmacol; 1979; 3(3):177-80. PubMed ID: 316745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
    Lokich JJ; Moore CL; Anderson NR
    Cancer; 1996 Jul; 78(2):294-9. PubMed ID: 8674006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of IV hydration with sodium bicarbonate on high-dose methotrexate disposition kinetics].
    Tsuda N; Goto M; Konishi H; Yamashina H
    Gan To Kagaku Ryoho; 1984 Apr; 11(4):873-80. PubMed ID: 6326682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions.
    Howell SB; Chu BB; Wung WE; Metha BM; Mendelsohn J
    J Clin Invest; 1981 Apr; 67(4):1161-70. PubMed ID: 6970753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of the cytostatic drugs used in the CMF-regimen.
    Slee PH; de Bruijn EA; Driessen OM; Hermans J; van Oosterom AT
    Anticancer Res; 1983; 3(4):269-71. PubMed ID: 6688337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic interactions of cyclophosphamide and 5-fluorouracil with methotrexate in an animal model.
    de Bruijn EA; Driessen O; Leeflang P; van den Bosch N; van Strijen E; Slee PH; Hermans J
    Cancer Treat Rep; 1986 Oct; 70(10):1159-65. PubMed ID: 3756938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I and pharmacology study of continuous-infusion low-dose methotrexate administration.
    Lokich JJ; Curt G
    Cancer; 1985 Nov; 56(10):2391-4. PubMed ID: 4042071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate. II. Use in pediatric chemotherapy.
    Lippens RJ
    Am J Pediatr Hematol Oncol; 1984; 6(4):397-413. PubMed ID: 6398630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion.
    Evans WE; Hutson PR; Stewart CF; Cairnes DA; Bowman WP; Rivera G; Crom WR
    Clin Pharmacol Ther; 1983 Mar; 33(3):301-7. PubMed ID: 6600662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pleural effusion on high-dose methotrexate kinetics.
    Evans WE; Pratt CB
    Clin Pharmacol Ther; 1978 Jan; 23(1):68-72. PubMed ID: 618710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of methotrexate in children.
    Wang YM; Fujimoto T
    Clin Pharmacokinet; 1984; 9(4):335-48. PubMed ID: 6380871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The protein binding and elimination of methotrexate after intravenous infusions in cancer patients.
    Paxton JW
    Clin Exp Pharmacol Physiol; 1982; 9(3):225-34. PubMed ID: 7140004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis.
    Bannwarth B; Péhourcq F; Schaeverbeke T; Dehais J
    Clin Pharmacokinet; 1996 Mar; 30(3):194-210. PubMed ID: 8882301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclophosphamide, methotrexate, and 5-fluorouracil in a three-drug admixture. Phase I trial of 14-day continuous ambulatory infusion.
    Lokich J; Bern M; Anderson N; Wallach S; Moore C; Beauchamp K; Williams D
    Cancer; 1989 Mar; 63(5):822-4. PubMed ID: 2914289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.